Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated assessment statements about DPD/DPYD-related toxicity risk and concomitant vitamin K antagonist (e.g., warfarin) bleeding/INR monitoring are directly supported by the provided XELODA prescribing information excerpts (Sections 5.1/2.1 and 5.2/7.2), with no identified contradictions.
Category Scores
Accurate Statements
Patients with certain DPYD gene variants causing complete DPD deficiency are at increased risk of acute early-onset toxicity and serious, including fatal, adverse reactions from XELODA.
Supported by label excerpts in 5.1 (and consistent with 2.1).
Prior to initiating XELODA, test patients for DPYD genetic variants unless immediate treatment is necessary.
Supported by label excerpts in 2.1.
Avoid use of XELODA in patients known to have certain homozygous/compound heterozygous DPYD variants resulting in complete DPD deficiency, and no XELODA dose is proven safe for complete DPD deficiency.
Supported by label excerpts in 5.1 (and consistent with 2.1).
XELODA concomitant use with vitamin K antagonists (e.g., warfarin) has been reported to cause altered coagulation parameters and bleeding, including death.
Supported by label excerpts in 5.2 (and consistent with 7.2).
Monitor INR more frequently and adjust the vitamin K antagonist dose as appropriate when XELODA and vitamin K antagonists are used concomitantly.
Supported by label excerpts in 5.2 and 7.2.
Unsupported Statements
Contradictions
Important Omissions
Assessment of other labeling elements (e.g., boxed warnings, contraindications, additional warnings/precautions, comprehensive adverse reaction listings, monitoring beyond INR for vitamin K antagonists, and storage/handling) was not evaluable because the provided label excerpts cover only DPD/DPYD testing/avoidance and vitamin K antagonist bleeding risk.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims concern label-supported high-risk safety warnings (DPD/DPYD deficiency and vitamin K antagonist bleeding) and include label-recommended testing/monitoring guidance, with no contradictions identified within the excerpted sections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Only the provided excerpted labeling sections were evaluated; other label components could not be assessed from the supplied text.
Suggested Improvement
Provide additional relevant FDA label sections (e.g., contraindications, boxed warnings, other warnings/precautions, full dosage/administration, other monitoring) if a comprehensive alignment audit is required.